BIBCL SHARE PRICE SHARE PRICE [LIVE]
| Open: | |
| High: | |
| Low: |
| MKT Cap: | |
| 52-wk High: | |
| 52-wk Low: |
| Prev close: | |
| P/E: | |
| Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
| Name | Dec 22 | Sep 22 |
|---|---|---|
| Promoters (Change:-0.00) | 59.25% | 59.25% |
| FIIs (Change:0.00) | 0% | 0% |
| Mutual Funds (Change:0.00) | 0% | 0% |
| Insurance Companies (Change:0.00) | 0% | 0% |
| Other DIIs (Change:-0.11) | 0% | 0.11% |
| Non Institution (Change:0.11) | 40.75% | 40.64% |
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in BIBCL SHARE PRICE
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
BIBCL News
Frequently Asked Questions
What is the Share price of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD. (BIBCL)?
Can I buy BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD. (BIBCL) shares?
How do I buy BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD. (BIBCL) from Angel One?
- Direct investment: You can buy BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD. (BIBCL) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD. (BIBCL) shares.
In which sector do BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD. (BIBCL) belong?
About BIBCL
Today's live share price for BIBCL SHARE PRICE is NSE: N/A, BSE: ₹ 23.60 with a current market capitalization of .
Incorporated in 1989 in Uttar Pradesh, Bharat Immunological & Biological Corporation (BIBCL) is in the business of manufacturing pharmaceutical formulations. The company's manufacturing unit is located in Bulandshahr district, Uttar Pradesh. BIBCL manufactures oral polio vaccine (OPV) for which it has installed a plant of 100 mln units. Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme. It has set up an R&D unit for the development of hepatitis B vaccine through transfer of technology from the US. The Company is planning to diversify into the production of vaccines pertaining to B.C.G, Measles and Tetanus Toxide.The company has been declared a SICK company by BIFR.
Read more
